Tamar Thompson

Tamar Thompson joined our Board on May 25, 2023. Ms. Thompson has served as Organization Head – Global Corporate Affairs for Alexion Pharmaceuticals/AstraZenenca Rare Disease, since 2021, when Alexion was acquired by AztraZenenca. Prior thereto, from 2019 to 2021, Ms. Thompson was Vice President, Global Corporate Affairs for Alexion Pharmaceuticals. Further, prior to joining Alexion, from February 2015 to November 2019, when she joined Alexion, Ms. Thompson served in several capacities for Bristol-Myers Squibb Company, most recently as executive director of State Government Affairs and Federal Policy. Prior to joining Bristol-Myers Squibb, Ms. Thompson was a strategic policy advisor and consultant for premiere Washington, DC based governmental affairs firms, including ADVI, Kimbell and Associates and Avalere Health. Finally, since 2020, Ms. Thompson has served as an independent director of Avidity Biosciences, Inc. (NASDAQ:RNA), where she serves on the Nominating and Governance Committee and on the Compensation Committee of that board. She also serves as Vice Chair of the board of directors of MassBio, a premier state level trade association representing the biotech sector in Massachusetts. Ms. Thompson holds an M.S. in Health Sciences with a concentration in Public Health from Trident University in Cypress, California. The Board believes that Ms. Thompson’s extensive health policy and government affairs experience, as well as her focus on rare diseases in her current position, have contributed to our Board of Directors’ conclusion that she should serve as a Director of our company.